Skip to content

EV / sales at other companies

Baxter International logo
Baxter InternationalBAX
0.6×-0.8×
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
2.7×-1.4×
Embecta Corp. logo
Embecta Corp.EMBC
1.6×-0.3×
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-0.1×
InfuSystem Holdings logo
InfuSystem HoldingsINFU
1.5×+0.4×
UFP Technologies logo
UFP TechnologiesUFPT
2.7×-0.5×

Other financials

Income statement

See full
Revenue$11.8M+22.1%
Gross profit$7.2M+19.6%
Operating income-$864.9K+30.5%
Net income-$807.1K+30.8%
EPS (diluted)-$0.02+33.3%

Balance sheet

See full
Cash & equivalents$8.8M+0.4%
Total debt$3.5M-2.8%
Total equity$16.9M+3.5%
Total assets$28.6M+5.1%

Cash flow

See full
Operating cash flow$14.7K+106%
CapEx$46.2K-89.6%
Free cash flow-$31.5K+95.4%

Valuation

See full
Market cap$206.24M+24.9%
Enterprise value$200.96M+25.1%
P/S4.8×+0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin-6%-2.3pp
Net margin-5.3%-2.1pp
FCF margin-37.1%+23.7pp

Returns & leverage

See full
Return on equity-13.7%-4.8pp
Debt / equity0.2×0.0×
Current ratio2.3×-0.1×

Where this comes from

Calculated from KORU Medical Systems’s reported figures.

Based on the most recent quarter.

The official record: KORU Medical Systems’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about KORU Medical Systems's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KORU Medical Systems's EV / sales?
KORU Medical Systems (KRMD) reported EV / sales of 4.5× in Q1 2026.
How has KORU Medical Systems's EV / sales changed year-over-year?
KORU Medical Systems's EV / sales increased by 41.8% year-over-year, from 3.2× to 4.5×.
What is the long-term trend for KORU Medical Systems's EV / sales?
Over 5 years (2020 to 2025), KORU Medical Systems's EV / sales has grown at a -8.2% compound annual growth rate (CAGR), from 9.8× to 6.4×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.